Open Access Research article

Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients

Wulf Siggelkow1, Daniel Boehm2, Susanne Gebhard2, Marco Battista2, Isabel Sicking2, Antje Lebrecht2, Christine Solbach2, Birte Hellwig3, Jörg Rahnenführer3, Heinz Koelbl2, Mathias Gehrmann4, Rosemarie Marchan5, Cristina Cadenas5, Jan G Hengstler5 and Marcus Schmidt26*

Author Affiliations

1 Department of Obstetrics and Gynecology, Diakonischen Dienste Hannover GmbH, Diakoniekrankenhaus Henriettenstiftung und Diakoniekrankenhaus Friederikenstift, Hanover, Germany

2 Department of Obstetrics and Gynecology, Johannes Gutenberg University, Mainz, Germany

3 Department of Statistics, Dortmund TU, Dortmund, Germany

4 Bayer GmbH, Leverkusen, Germany

5 IfADo-Leibniz Research Centre for Working Environment and Human Factors (IfADo), Technical University of Dortmund, Dortmund, Germany

6 Department of Obstetrics and Gynecology, University of Mainz, Langenbeckstr. 1, Mainz, 55131, Germany

For all author emails, please log on.

BMC Cancer 2012, 12:562  doi:10.1186/1471-2407-12-562

Published: 27 November 2012

Additional files

Additional file 1:

Table S1. Cox analysis of metastasis free survival (MFS) in the single cohorts, in the combined cohort and in the molecular subtypes (ER+/HER2-, ER-/HER2-, HER2+) according to Desmedt (2008). The proliferation metagene is associated with MFI in the estrogen receptor positive but not in the estrogen receptor negative subtypes. Figure S1: Scatter plots showing correlation of AURKA probe sets. Whereas 208079_s_at and 204092_s_at highly correlate with each other the probe set 208080_at shows poor correlation with the other two. Table S2: Similarly as the probe set described in the main manuscript (204092_s_at) the AURKA probe set 208079_s_at is associated with metastasis-free survival (MFS) in the three independent cohorts of systemically untreated node negative breast cancer (combined Mainz, Rotterdam and Transbig cohorts, n=766). HR: hazards ratio, 95%-CI: 95% confidence interval. AURKA was analyzed as a continuous variable. Table S3: Cox analysis of metastasis-free survival (MFS) in the molecular subtypes (ER+/HER; ER-/HER2-; HER2+) according to Desmedt (2008). The AURKA probe set 208079_s_at is associated with MFI in the estrogen receptor positive but not in the estrogen receptor negative subtypes, as described for 204092_s_at in the main manuscript. A. Univariate analysis, B. Multivariate Cox regression (DOC 162 kb)

Format: DOC Size: 163KB Download file

This file can be viewed with: Microsoft Word Viewer

Open Data

Additional file 2::

Figure S1. Metastasis free survival likeliehood statistics as described by Prat et al., (2012). To compare the amount of independent prognostic information provided by Ep-CAM (A) and AURKA (B) we estimated the likelihood ratio statistic in a model that already included AURKA (A) or Ep-CAM (B). The model shows that AURKA provides significant additional information over grading in the cohort of all patients, as well as in the ER+/HER2- subgroups (B). Vice versa, Ep-CAM provides additional information over AURKA only in the cohort of all patients. (PPT 182 kb)

Format: PPT Size: 183KB Download file

This file can be viewed with: Microsoft PowerPoint Viewer

Open Data